Citadel Advisors
ANVS icon

Citadel Advisors’s Annovis Bio ANVS Stock Holding History

Citadel Advisors’s Portfolio ANVS Stock Details ANVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$275K Buy
148,000
+89,700
+154% +$174K ﹤0.01% 11320
2026
Q1 		$130K Buy
58,300
+14,900
+34% +$40.9K ﹤0.01% 11806
2025
Q4 		$150K Buy
43,400
+4,800
+12% +$14.4K ﹤0.01% 11321
2025
Q3 		$79.9K Buy
38,600
+4,700
+14% +$11.7K ﹤0.01% 11975
2025
Q2 		$73.6K Sell
33,900
-42,800
-56% -$84.5K ﹤0.01% 11553
2025
Q1 		$115K Sell
76,700
-228,800
-75% -$700K ﹤0.01% 11260
2024
Q4 		$1.54M Buy
305,500
+40,900
+15% +$296K ﹤0.01% 6175
2024
Q3 		$2.13M Buy
264,600
+126,700
+92% +$1.19M ﹤0.01% 5416
2024
Q2 		$794K Buy
137,900
+20,800
+18% +$169K ﹤0.01% 7055
2024
Q1 		$1.39M Buy
117,100
+114,800
+4,991% +$1.25M ﹤0.01% 6239
2023
Q4 		$43K Buy
+2,300
New +$20.4K ﹤0.01% 11941

Other funds holding ANVS

EAM
Empery Asset Management New York $86.5M AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors's ANVS Position: Q2 2026 in Review

Citadel Advisors opened a new position in Annovis Bio (ANVS) in Q2 2026: 243,682 shares worth $453K. The stake represents ﹤0.01% of the portfolio and ranks #10102 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ANVS as recently as Q3 2025.

Citadel Advisors first reported a position in ANVS in Q1 2021 and has held it in 9 quarters since. The position peaked at $1.18M in Q3 2021. 61 funds tracked by Wall St. Rank hold ANVS as of Q2 2026.

  • Citadel Advisors held 243,682 shares of Annovis Bio worth $453K as of Q2 2026.
  • Annovis Bio was a new Citadel Advisors position in Q2 2026.
  • Annovis Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #10102 holding.
  • Citadel Advisors first reported a position in Annovis Bio in Q1 2021 and has held it in 9 quarters since.
  • Citadel Advisors's Annovis Bio position peaked at $1.18M in Q3 2021.
  • 61 funds tracked by Wall St. Rank held Annovis Bio as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.